Overall survival data for Imfinzi: Stage III NSCLC
25 September 2018 13:15 BST Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer Imfinzi reduced the risk of death by nearly one third compared to standard of care in the Phase III PACIFIC trial Updated data reaffirm unprecedented improvement in progression-free survival of more than 11 months AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi during the Presidential Symposium of the IASLC 19th